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Nasal allergies are prevalent aﬀecting a large percentage of the population. Not only the upper respiratory tract but the whole
body is involved. Allergies produce morbidity (and even occasional mortality) as they can lead to asthma development, and
increased number of accidents. Immunotherapy results can be evaluated by following symptom scores, medication use, and
objective measurements. Using a Peak Flow Meter (PFM) to evaluate immunotherapy results, it became evident that patients
with and without asthma exhibited an improvement in the Peak Flow (PF) value, suggesting that lower airway involvement in
allergic patients could be more prevalent than assumed. A consecutive chart review was performed including patients of any age
with nasal allergies (with or without asthma) treated with immunotherapy for at least 6 months that had at least 2 complete
evaluations. When immunotherapy was successful, most patients exhibited an increase in the PF value regardless of asthma status.
A very signiﬁcant ﬁnding was that most allergy suﬀerers may have lower airway inﬂammation. The use of the PF value to assess
immunotherapy results and the potential failure to diagnose asthma in allergy suﬀerers are discussed. A better diagnosis of lower
airway inﬂammation could be substantial in the management of these patients.
1.Introduction
Nasal allergies are common and their prevalence in industri-
alized societies appears to be increasing. While nasal allergies
were rarely diagnosed in the 19th century, their occurrence
markedly increased during the 20th century. For example,
studies show the incidence of nasal allergies in parts of the
United States at 10% in 1974, 20% in 1986, and 42% in 1994
[1]. Similar ﬁgures of up to 40% have been reported in other
parts of the world too [2]. In addition, similar increases have
occurred in conditions not usually associated with allergies
but with clear allergic etiology, such as eczema and asthma.
Theseﬁguresindicateanexplosiveincrease.Itispossiblethat
an increasingly polluted environment is a causative factor
[1].
Asthma is a common chronic disorder of the airways
characterized by an underlying inﬂammation that leads
to bronchial hyperresponsiveness and recurring airﬂow
obstruction. In some cases patients develop persistent
changes in airway structure, including ﬁbrosis, smooth
muscle hypertrophy, and angiogenesis. In the United States
asthma aﬀects more than 22 million people. It is one of the
most common chronic diseases of childhood, aﬀecting more
than six million children in the USA [3].
The occurrence of asthma also has increased. Hospital-
ization rates are higher among young children. Collectively,
individuals with asthma account for more than 497,000
hospitalizations annually. The onset of asthma for most
patients begins early in life with the pattern of disease
persistence. Recognizable risk factors include atopic disease.
Current asthma treatment with anti-inﬂammatory therapy
does not appear to prevent progression of the underlying
disease severity [3].
The allergic disease aﬀects the whole body. Fatigue is one
of the most common complaints of the allergy suﬀerer, [4]
and nasal congestion is recorded as the most bothersome
symptom of allergic rhinitis [5]. Nasal obstruction is often
the most severe symptom in patients with nasal allergies and
it can lead to the onset or worsening of obstructive sleep
apnea (OSA) [6].
Sleep-related symptoms are extremely common in
patients with allergic rhinitis. Sleep impairment associated2 Journal of Environmental and Public Health
with allergic rhinitis is likely a major contributor to the
overall disease morbidity, health care costs, and loss of work
productivity [7].
Individuals with OSA are at an increased risk for motor
vehicle accidents [8] and lack of sleep has been implicated
in job related accidents as well. [9] In addition, there
are patients where the inﬂuence of nasal obstruction in
sleep disordered breathing is critical [10]. Nasal obstruction
also is a contributing factor to development of dentofacial
abnormalities in the developing child [11].
So it is clear that having allergies means dealing with
more than just nasal congestion, rhinorrhea, and itchy eyes.
Notonlycanqualityoflifebesigniﬁcantlyimpairedforthose
with allergies, but also this condition can be potentially life
threatening given that a patient with allergies is susceptible
to fatigue, sleep deprivation, a higher incidence of accidents,
and lower airway inﬂammation with bronchoconstriction.
While medical management of nasal allergies will control
symptoms in the best of circumstances, immunotherapy is
the only treatment modality available that can potentially
cure the allergic condition [12, 13]. Immunotherapy works
by modifying the immunological response of the allergic
individual through stimulating the production of IgG (usu-
ally known as a “blocking antibody”) and eliciting more
complex changes in the activity of the T-cells [14], where T-
cell tolerance is attained mainly by generation of allergen-
speciﬁc Treg cells leading to suppressed T-cell proliferation
and Th1 and Th2 cytokine responses against the allergen.
This is accompanied by a signiﬁcant increase in allergen-
speciﬁc IgG4,I g G 1, and IgA and a decrease in IgE in the late
stage of the disease [13].
In the clinical setting immunotherapy treatment is
usually evaluated by following changes in symptoms scores.
Speciﬁcally, the patient rates his/her symptoms usually using
a numerical scale, and the change of this value over time
is followed to assess improvement or lack thereof. Even
though this is a subjective tool, diﬀerent symptoms scores
have been scientiﬁcally validated as useful [15–17]. Some of
the objective measurements of symptomatic improvement
include use of acoustic rhinomanometry [18].
In our oﬃce we use a symptom questionnaire (see
Figure 1) based on the scoring method followed by Fell
[17]. We added objective measurements including nasal
resistance determined by acoustic rhinomanometry and
determination of PF value. While acoustic rhinomanometry
requires signiﬁcant training of the technician, it is time
consuming, and yields results that are diﬃcult to interpret,
using a PFM device requires minimal training and yields
easy-to-interpret results in seconds. It became clear that
determining the PF value was a simpler procedure that
could be easily incorporated in a private practice clinical
setting. Soon after the use of the PFM was incorporated
in our practice, it was observed that patients with allergies
exhibited an improvement in PF value if immunotherapy
was successful (as measured by a decrease in symptom scores
and medication use) and that such improvement occurred
not only in the patients with asthma but also in the allergy
suﬀerer without any asthma symptoms.
Table 1: Symptoms considered for scoring.
Sneezing
Runny nose
Nasal obstruction
Post nasal drip
Watery eyes
Itchy eyes
Itchy ears
Itchy nose
Itchy throat
Itchy skin
Clogged ears
Facial pain/pressure
Headaches
Cough
Sensation of tight chest
Wheezing
Shortness of breath
Exercise-induced SOB
Exercise-induced cough
Exercise-induced wheezing
Waking up with symptoms
To verify this hypothesis, we collected the data presented
herein, with the understanding that this is only an observa-
tional study that lacks the rigor of a prospective randomized
study with a control group.
2. Methods
A consecutive chart review was performed. Inclusion criteria
for the study were patients of any age with nasal allergies
(withorwithoutasthma)treatedwithimmunotherapyforat
leastsixmonthsthathadatleasttwocompleteevaluations.A
complete evaluation included symptom scoring, evaluation
of medication use, and determination of PF value.
Ethical Considerations. Subjects’ privacy was assured by
the way data was collected and recorded so that subjects
could not be directly or indirectly identiﬁed. In other
words, a patient’s privacy was protected by entering data for
statistical analysis in a simple spreadsheet with nonspeciﬁc
identiﬁers, such as patient number 1 and patient number 2,
with subsequent reﬁling of the patient’s chart according to
usual procedure.
InourpracticewefollowFell’smethod[17]forsymptom
scoring, which classiﬁes each symptom with a numerical
analog from 0 through 3 as follows:
0: symptom is not present,
1: symptom is mild,
2: symptom is moderate,
3: symptom is severe.
There were 21 symptoms considered for this evaluation (see
Table 1). The symptom score was obtained by adding theJournal of Environmental and Public Health 3
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Cough
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values of each symptom (0–3) in each patient; the maximum
total symptom score was 63. The total number of symptoms
also was considered for monitoring clinical response.
When considering clinical response to immunotherapy,
the use of medications is monitored as well. Patients that do
notexhibitadecreaseinmedicationusewiththeadministra-
tionofimmunotherapyarereassessed.Forthisevaluationwe
considered use of allergy pills (antihistamines or leukotriene
receptor antagonists), intranasal topical steroids, and short
acting bronchoagonists. No patient in this study was on oral
or systemic steroids or decongestants.
For evaluation of medication use we use a similar
numerical scale as follows:
0: medication is not being used,
1: medication is being used once a week or less,
2: medication is being used 2 to 3 times per week,
3:medicationisbeingused4ormoretimesperweek.
The maximum total medication score was 9 and the
maximum total number of medications was 3. When
immunotherapy is successful, medication use will decrease
regardless of the type of medication. In the asthmatic
patient, asthma inhalers will be used less frequently or even
discontinued entirely in the more successful outcomes.
The value of the PFM determination is used as the
parameter to be recorded during each patient’s visit.
The sample included adults and children with or without
asthma treated with subcutaneous injection immunotherapy
(SCIT) or sublingual immunotherapy (SLIT). Antigens were
mixed according to results of an intradermal dilutional test.
The data presented here was not analyzed according to test
results. Patients on SCIT were treated according to American
Academy of Otolaryngic Allergy (AAOA) guidelines [19].
Patients on SLIT were treated according to a previously
published protocol [20]. The formulation of both injectable
and oral allergy-vaccines was the same; based on allergy test
results, all positive allergens were included in the treatment
mixture.
Asthma symptoms considered included cough, sensation
of tight chest, wheezing, shortness of breath (SOB), exercise-
induced symptoms (cough, SOB, wheezing), or waking
up at night with any of those symptoms. Presence of
asthma symptoms in patients who considered themselves
“nonasthmatic” was also analyzed.
Sixty charts that met inclusion conditions were identi-
ﬁed. They were analyzed using the same criteria regardless if
patients were treated with SCIT or SLIT. For each patient we
evaluated total symptoms score, total number of symptoms,
medication score, total number of medications used, and the
PFvalue,whichwasobtainedbeforetreatmentinitiationand
at least once more at the time of data collection.
The changes of the above parameters during the admin-
istration of immunotherapy were evaluated. In determining
the results between two or more groups of patients, an
ANOVA (Analysis of Variance) was performed using the PF
performance as the dependent variable. When determining
signiﬁcance between continuous variables, a bivariate corre-
lation analysis was performed.
Asthma symptoms
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Figure 2: Total sample and subgroups. Total sample: 60 subjects, 13
reportasthma,47donot.Totalsamplesubdivided:13reportasthma,
Remainder 47: 30 have cough and other asthma symptoms, 11 have
coughonly,and6havenocoughorotherasthmasymptoms.Cough:
53/60 subjects had cough.
3. Results
3.1. Demographics. The total sample included 60 subjects,
ages 4 through 75 (mean 41.1 ± 17.5). Mean length of
treatment was 22.9 ± 13.1 months. In 42 of 60 patients
(70%), treatment extended for more than 12 months.
3.2. Asthma. A diagnosis of asthma was self-reported by
13 subjects (21% of the total sample), and only 1 of these
subjects did not report cough as one of the symptoms. The
remaining 47 subjects denied having asthma, although 30
reported asthma symptoms (30/47 = 63.8%) (see Figure 2).
The group of 47 patients that did not report asthma were
divided into three subgroups (see Figure 2):
(a) patients with cough and other asthma symptoms: 30,
(b) patients with cough but no other asthma symptoms:
11,
(c) patients without cough (and no other asthma symp-
toms): 6.
3.3. Cough. Cough was reported by 53 out of 60 patients in
this sample (88%). Eleven out of these 53 (subgroup b) had
noothersymptomssuggestiveoflowerairwayinﬂammation.
While it can be assumed that a patient with cough and
other symptoms of lower airway inﬂammation has asthma,
a patient with cough and no other symptoms is a diﬀerent
situation. Even though it is proven that cough can be
the only symptom a patient with asthma may present, no
further conclusions can be made without information on
spirometric results or response to bronchodilator and/or
anti-inﬂammatory therapy (see Figure 2).
Because all the information in this report comes from
the symptom scoring sheet and not from oﬃce notes, weJournal of Environmental and Public Health 5
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Figure 3: Percentage of PF value change in relation to the number
of PF determinations. 2PF: two PF determinations. 3PF: three
PF determinations. 4+PF: four or more PF determinations. The
number of PF measurements is positively associated with the
percentage of PF change (r = 0.357, P<0.01).
decided to consider the group “cough but no other asthma
symptoms” as a separate group (see Discussion).
Adding the number of patients with asthma to the
number of patients with cough and other asthma symptoms
(13 + 30 = 43) suggests that 72% (43/60 = 71.6%) of the
patients in a group of nonselected allergy patients are indeed
asthmatic, and this is, at best, a conservative number as some
of patients with “cough only” could also be asthmatic.
3.4.PFChanges. AveragePFchangeforall60patientsduring
immunotherapy increased from 376.23 (±115.01) at the
beginning of treatment to 472.65 (±127.47) at the time of
data collection for an overall improvement of 25.63%. From
the total sample, 53 out of the 60 subjects (88.33%) showed
an improvement in PF value, 4 had a worsening of PF value,
and 3 had no change. Of the 53 subjects that showed an
i m p r o v e m e n ti nP Fv a l u e ,4 8h a dad e c r e a s ei ns y m p t o m s
score and number of symptoms. Therefore a PF increase has
a predictor value of 90.57% for clinical improvement of the
patient.
While an increase in the PF value is strongly associated
with a symptomatic improvement (48/53), a decrease in the
PF value is not necessarily associated with clinical worsening:
of the 4 subjects with a worse PF value, all still had a
decreasedsymptomscoreand3hadadecreaseinthenumber
of symptoms. Of the 3 subjects with no change in the PF
value, 2 got better (decrease in symptoms scores and number
of symptoms) and 1 got worse.
3.5. PF Changes in Relation to the Number of Measurements.
In 11 patients there were 2 PF value measurements, one
at the beginning of the treatment and the second one
at the time of data collection (see Figure 3). Average PF
change during immunotherapy for these patients ranged
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Figure 4: Number of subjects that had improved PF values
in diﬀerent groups. Whole group: 53/60; Asthma: Self-reported
asthma patients: 11/13; No asthma: Patients that denied asthma:
42/47; Asthma Symptoms: Patients that denied asthma but had
asthma symptoms: 26/30; Cough: Patients that denied asthma and
had cough but no other asthma symptoms: 10/11; No cough:
Patients that denied asthma and had NO cough and NO other
asthma symptoms: 5/6. ANOVA showed no signiﬁcant diﬀerence
in average percentage of PF change of the aforementioned groups
(F = 0.975, P = N/S). >18 No Asthma: Patients older than 18
years of age that did not report asthma: 38/42. >18 Asthma:Patients
older than 18 years of age that reported asthma: 7/9.
from 390.00 (±115.84) to 453.55 (±161.36), for an overall
improvement of 16.29%.
In 13 patients there were 3 PF value measurements.
Average PF change during immunotherapy for these patients
ranged from 368.46 (±109.76) to 459.23 (±103.23), for an
overall improvement of 24.63%.
In 36 patients there were 4 or more PF value mea-
surements. Average PF change during immunotherapy for
these patients spanned from 374.83 (±119.37) to 483.33
(±126.49), for an overall improvement of 28.95%.
A bivariate correlation analysis showed that the number
ofPFmeasurementsispositivelyassociatedwiththepercent-
a g eo fP Fc h a n g e( r = 0.357, P<0.01). Therefore when
more PF measurements are obtained, it is more likely to
obtain a greater improvement in the PF value.
3.6. PF Value in Relation to Length of Treatment. There is a
positive correlation between the change in the PF value and
the number of months that the patient was treated (r =
0.253, P<0.05).Inotherwords,thelongerapatientreceives
immunotherapy the more likely the PF value will increase.
3.7. PF Changes in Diﬀerent Groups. PF changes were evalu-
ated in patients that reported asthma and in the subgroups
of the patients that did not report asthma (see Figure 4).
Patients That Reported Asthma. In the 13 patients who self-
reported having asthma, the average PF value increased
from 315.69 (±124.85) to 385.38 (±85.40), for an overall
improvement of 18.08%. Eleven out of the 13 patients had
an improvement in the PF value (84.62%). Two got worse
(15.38%).6 Journal of Environmental and Public Health
Patients That Did Not Report Asthma. In the group of 47
patients that did not report asthma, 42 (89.36%) had an
improvement in the PF value, 3 did not improve (6.38%),
and 2 decreased (4.26%). This group of 47 patients can be
divided in 3 subgroups.
(a) For the thirty patients that did not report asthma
but had asthma symptoms, the average PF value in-
creased from 398.33 (±114.11) to 492.30 (±139.40),
for an overall improvement of 23.59%. Twenty-six
out of the 30 patients had an improvement in the
PF value (86.67%). Three patients did not show any
improvement (10.00%), and 1 got worse (3.33%).
(b) For the eleven patients that had cough but no other
symptoms suggestive of lower airway inﬂammation,
theaveragePFvalueincreasedfrom376.36(±109.39)
to 510.91 (±105.49), for an overall improvement
of 35.75%. Ten out of the 11 patients had an
improvement in the PF value (90.91%). In 1 patient
the PF value decreased (9.09%).
(c) For the six patients that had no cough or any other
symptom suggestive of lower airway inﬂammation,
the average PF value increased from 396.67 (±79.16)
to 493.33 (±115.87) for an overall improvement of
24.37%. Five out of 6 patients had an improvement
in the PF value (83.33%). In 1 patient the PF value
decreased (16.67%).
An ANOVA showed that there is no signiﬁcant diﬀerence
among the average percentage of PF change of the aforemen-
tioned groups (F = 0.975, P = N/S).
3.8. Age. Because children can grow during a multiyear
treatment (e.g., children between 3 and 13 years of age grow
approximately 2 inches per year, and 2 inches can determine
an increase of 15 to 25 points in PF value depending on
the patient’s sex), the same calculations were done excluding
patients younger than 18 years of age. There were 51 patients
older than 18 years of age.
The average PF value in these 51 patients (see Figure 4)
changed from 395.76 (±110.01) to 495.49 (±120.97), for an
overall improvement of 25.20%. In this group there were
9 patients (17.65%) that reported asthma and 42 patients
(82.35%) that did not report asthma.
In the 42 patients that did not report asthma the PF value
improved from 404.29 (±106.84) to 515.48 (±118.02), for
an overall improvement of 27.50%. Thirty-eight out of the
42 showed an improvement in PF value (90.48%). The PF
value did not change in 2 patients (4.76%) and decreased in
2 others (4.76%).
In the 9 patients that reported asthma, the PF value
improved from 356.00 (±122.38) to 402.22 (±90.52), for an
overall improvement of 12.98%. In 7 out of the 9 patients the
PF value showed an improvement (77.78%). The PF value
decreased in 2 (22.22%).
3.9.PatternofPFChange. Itwasobservedthatpatientscould
be divided into 2 groups according to the way the PF value
changed during the administration of immunotherapy: in
the ﬁrst group the PF determination increased each time
it was obtained, and in the second group the PF value
ﬂuctuated during the course of immunotherapy even though
the value at the time of data collection was generally higher
than the initial value.
Thirty-six patients (36/60: 60%) belonged to the ﬁrst
group (sustained improvement), and twenty-one patients
(21/60: 35%) belonged to the second group (PF value cycled
up and down). Three patients did not have any changes in
the PF value (3/60: 5%).
In the ﬁrst group 35 out of 36 patients (97%) had
a decrease in the symptoms score, and 34 out of 36
patients (94%) had a decrease in the number of symptoms
(coincident with an increase in the PF value).
For patients that consistently improved (35 of 60), the
diﬀerence in symptom scores for those that had 5 or more
PF value measurements was statistically higher than that for
those that had fewer than 5 determinations (F = 5.02, P<
0.05). Number of symptoms also exhibited a similar pattern
when comparing the same 2 groups (F = 6.42, P<0.05).
4. Discussion
Patients with symptoms suggestive of lower airway inﬂam-
mation may not consider themselves as asthmatic, but it is
likely they are. A patient that only exhibits cough could be
asthmatic, but unless an improvement in spirometric values
after administration of bronchodilators is demonstrated
or symptom improvement occurs after administration of
asthma drugs, it is not possible to establish that patient as
asthmatic.
Our sample consisted of 60 patients with allergies that
were not screened for the presence of asthma. Of those
patients, 13 self-reported having asthma and 30 reported
experiencing asthma symptoms but did not report asthma,
meaningthatanimpressive71.67%ofoursamplepotentially
could be asthmatic. If the patients with cough but no other
asthma symptoms were also considered, then this percentage
could be even higher. If this ﬁnding is extrapolated to all
allergy suﬀerers, it can then be assumed that the majority
of allergy suﬀerers consulting an allergy practice might be
asthmatic. It is clear that asking a patient if he/she is asth-
matic is not suﬃcient; rather the presence of each symptom
of asthma needs to be addressed. Patients with asthma are
often at higher risk for severe reactions not only during
the administration of immunotherapy [21, 22] but also
during testing, and these patients should be considered more
sensitive[23].Fatalitiesfromimmunotherapy,althoughrare,
are more common in asthmatics [24, 25]. Given all this, it
is important to establish if an allergy patient is asthmatic
or not, as a diagnosis of asthma aﬀects quality of life as
well as morbidity, and it can also potentially impact the life
expectancy of that patient.
There is a tendency to consider asthma and allergic
rhinitis (AR) as two separate entities, but there is strong
evidence that this is not so. The term rhinobronchitis has
been proposed to help recognize the concept of chronicJournal of Environmental and Public Health 7
inﬂammation throughout the entire airway in the patient
with concurrent allergic rhinitis and asthma [26]. Up to 19%
of hay fever suﬀerers develop asthma later in life [27]. Nasal
challenge with environmental stimuli (such as cold air) leads
to bronchoconstriction [26, 28]. Some AR patients with no
perceived asthma develop bronchial hyperreactivity during
AR exacerbation [26]. All this data supports the concept that
the upper and lower airways are a unique entity impacted by
a common, evolving inﬂammatory process. Therefore from
an immunotherapeutic point of view, AR and asthma should
be considered a single entity [29], and the results reported
here support the concept of the Uniﬁed Airway [30]. If
the allergic reaction inﬂuences the whole body, it is only
logical that the bronchi will be involved in the widespread
inﬂammation that aﬀects the allergy suﬀerer.
There were 6 patients in the sample of 60 that were
deﬁnitely not asthmatic. In these patients the average PF
value improved 24.37%, and the PF value increased in 5
of 6 cases (83.33%). Both of these ﬁgures are in range
with the other groups, which supports the idea that even
nonasthmatic patients with nasal allergies still have lower
airway inﬂammation. This explains why, even when a patient
reports no asthma symptoms, the pulmonary function as
assessed by the PF value improves with treatment. With this
in mind, nasal allergies and asthma should be considered a
continuumofthesamediseasethatexpressesitselfdiﬀerently
in each patient; for certain individuals this means that the
nose and the eyes will be more aﬀected, and for others
it means that the lower respiratory system will be more
substantially impacted. However, it is a disease that at all
times, even if to a minimal degree, probably involves all the
organ systems.
Thisconceptisdiﬃcultforpatientstoaccept,andweﬁnd
that when patients with hyperreactive airway are told they
have asthma, the usual response is to deny the possibility.
Still this is an important concept when treating patients
with immunotherapy, since, as mentioned earlier, asthmatic
patients are more likely to experience reactions [21, 22].
These results should contribute to raising awareness that
potentially any patient presenting with allergy symptoms
could also have lower airway hyperreactivity. As previously
stated, the ﬁgure of 72% is possibly a conservative estimate;
and if patients that had cough but no other asthma symp-
tomswereconsideredaspatientswithairwayhyperreactivity,
thenumbercouldbeevenhigher.Inotherwords,inasample
of 60 nonselected allergy patients, it is possible that up to
90% ([13 + 30 + 11]/60) were asthmatic.
Having any symptoms suggestive of lower airway inﬂam-
mation (and cough is one that is very frequently found)
should lead to a work up to rule out the presence of a
hyperreactive lower airway. We feel that if this was the case,
the frequency of asthma-related diagnoses would markedly
increase.
The fact that when more PF measurements are obtained
the PF value will be higher could be related to the ﬁnding
that the longer the number of months the patient is treated
with immunotherapy the higher the PF value will be. This
suggests that the longer the treatment, the better the results,
regardlessofthepresenceofasthmasymptomsandageofthe
patient.Inotherwordsitappearsthatimmunotherapy,when
successful, leads to improvement of pulmonary function in
all patients with allergies.
Immunotherapy is a treatment that can modify the
immunological mechanisms that cause allergy symptoms
[12]. It is an old treatment modality [31] that is proven to
be eﬀective [32–34]. With immunotherapy, it is expected
that medication use will decrease, regardless of when the
medication was started and which medication was used.
When the treatment is fully successful, medications can be
stopped. We only analyzed medication use, as the purpose
of this study was not to address potential diﬀerences in
eﬀects of various medications, but to demonstrate that with
immunotherapy medication use diminishes.
Thisisaretrospectivestudyand,assuch,itlacksthevalue
of a prospective, randomized study with controls, which is
very diﬃcult to perform in private practice settings. The
information reported in this study suggests that a PFM
device could be useful in monitoring a patient’s progress
during immunotherapy, as changes in PF value can predict
how a patient is doing from a clinical standpoint. The
information it provides is available immediately, oﬀering a
quick assessment of patient’s progress.
WhenPFvalueconsistentlyimproves,thepredictorvalue
of the PF change is very high. However, in a few cases these
ﬁndings are relative: in some cases we observed that with an
unchanged or decreased PF value, a patient can still expe-
rience some improvement (decreased symptom/medication
score). We also found that with a better PF value, the patient
can have clinical worsening (increased symptom/medication
score). Overall, it appears that following a patient’s PF value
during immunotherapy is a good indicator of how he/she
is responding to the treatment: a decrease in PF value can
be used to predict that a patient is not doing well, and an
increase in PF value can be used to predict that a patient is
doingwell,particularlyiftheincreaseinPFvalueissustained
over time.
We hope that this information will serve as a stimulus
for authors in research facilities to plan a randomized
prospective study with a control group where the usefulness
of a PFM can be more properly evaluated.
5. Conclusion
Patients with nasal allergies that deny having asthma often
haveasthma symptoms. In ourstudy, thisoccurred in atleast
72% of the patients that denied having asthma. Therefore
when taking a patient’s history, it is critical to ask about
the presence of each symptom of asthma, regardless of the
patient’s perception of asthmatic status.
If it is accepted that the allergic condition aﬀects the
whole organism, then it is only logical that the lower airway
of an allergy suﬀerer will be involved. While the degree of
involvement varies according to the individual, it appears
from this data that the proportion of individuals with
aﬀectation of the lower airway is staggering. Perhaps then
it is time to reassess the deﬁnition of asthma. A “looser”
term such as lower airway inﬂammation or airway hyperre-
activity would be more inclusive of all patients with asthma8 Journal of Environmental and Public Health
symptoms. Even the term rhinobronchitis [26] should be
considered, as patients often reject the label of asthmatic.
Regardless, it appears that lower airway inﬂammation is
common and treatment of this inﬂammation either by
anti-inﬂammatory inhaled corticosteroids, immunotherapy,
or detoxifying interventions [35] could not only treat the
present condition but perhaps, more importantly, prevent
the development of irreversible lower airway remodeling.
Change in PF value can give a rapid assessment of how a
patient is responding to treatment. When PF value increases,
it is likely that a patient will improve in the majority of cases.
In cases where the PF value is better in each determination,
the PF has a 94% to 97% predictor value that the patient is
doing well.
When PF value improves during the administration of
immunotherapy, these changes are independent of asthmatic
condition, the presence of any or no asthma symptoms, or
the patient’s age. Only length of treatment and number of PF
measurements are related to an improved PF value.
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